Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.
Alcon tried to sink Aurion’s IPO in ‘Valentine’s Day massacre,’ new lawsuits say
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS